111 related articles for article (PubMed ID: 12865628)
1. Tumor antigens and antigen-presenting capacity in breast cancer.
McDermott RS; Beuvon F; Pauly M; Pallud C; Vincent-Salomon A; Mosseri V; Pouillart P; Scholl SM
Pathobiology; 2002-2003; 70(6):324-32. PubMed ID: 12865628
[TBL] [Abstract][Full Text] [Related]
2. T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer.
Nijman HW; van Diest PJ; Poort-Keesom RJ; von Mensdorff-Pouilly S; Verstraeten RA; Kummer A; Meijer CJ; Melief CJ; Hilgers J; Kenemans P
Eur J Obstet Gynecol Reprod Biol; 2001 Jan; 94(1):114-20. PubMed ID: 11134836
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of invariant chain (Ii) and Her-2/neu expression in curatively resected colorectal cancer.
Rossi HA; Liu Q; Banner B; Hsieh CC; Savas L; Savarese D
Cancer J; 2002; 8(3):268-75. PubMed ID: 12074327
[TBL] [Abstract][Full Text] [Related]
4. HLA-DRB alleles are differentially expressed by tumor cells in breast carcinoma.
Oldford SA; Robb JD; Watson PH; Drover S
Int J Cancer; 2004 Nov; 112(3):399-406. PubMed ID: 15382064
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
6. Effect of invariant chain on major histocompatibility complex class I molecule expression and stability on human breast tumor cell lines.
Lin X; Wang X; Capek HL; Simone LC; Tuli A; Morris CR; Reber AJ; Solheim JC
Cancer Immunol Immunother; 2009 May; 58(5):729-36. PubMed ID: 18828016
[TBL] [Abstract][Full Text] [Related]
7. Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients.
Janssen N; Fortis SP; Speigl L; Haritos C; Sotiriadou NN; Sofopoulos M; Arnogiannaki N; Stavropoulos-Giokas C; Dinou A; Perez S; Pawelec G; Baxevanis CN; Shipp C
Breast Cancer Res Treat; 2017 Jan; 161(1):51-62. PubMed ID: 27787640
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous bilateral breast carcinomas: a category with frequent coexpression of HER-2 and ER-alpha, high Ki-67 and bcl-2, and low p53.
Bassarova AV; Nesland JM; Sedloev T; Lilleby W; Hristova SL; Trifonov DY; Torlakovic E
Int J Surg Pathol; 2005 Jul; 13(3):239-46. PubMed ID: 16086078
[TBL] [Abstract][Full Text] [Related]
9. Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo.
Bai L; Beckhove P; Feuerer M; Umansky V; Choi C; Solomayer FS; Diel IJ; Schirrmacher V
Int J Cancer; 2003 Jan; 103(1):73-83. PubMed ID: 12455056
[TBL] [Abstract][Full Text] [Related]
10. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of DF3, in association with ICAM-1 and MHC class II by IFN-gamma in short-term human mammary carcinoma cell cultures.
Sgagias MK; Nieroda C; Yannelli JR; Cowan KH; Danforth DN
Cancer Biother Radiopharm; 1996 Jun; 11(3):177-85. PubMed ID: 10851535
[TBL] [Abstract][Full Text] [Related]
12. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.
Nielsen JS; Sahota RA; Milne K; Kost SE; Nesslinger NJ; Watson PH; Nelson BH
Clin Cancer Res; 2012 Jun; 18(12):3281-92. PubMed ID: 22553348
[TBL] [Abstract][Full Text] [Related]
13. p53 mutations in benign breast tissue.
Millikan R; Hulka B; Thor A; Zhang Y; Edgerton S; Zhang X; Pei H; He M; Wold L; Melton LJ
J Clin Oncol; 1995 Sep; 13(9):2293-300. PubMed ID: 7666086
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
15. CD1a and CD1d genes polymorphisms in breast, colorectal and lung cancers.
Golmoghaddam H; Pezeshki AM; Ghaderi A; Doroudchi M
Pathol Oncol Res; 2011 Sep; 17(3):669-75. PubMed ID: 21258883
[TBL] [Abstract][Full Text] [Related]
16. The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules.
Watts C
Nat Immunol; 2004 Jul; 5(7):685-92. PubMed ID: 15224094
[TBL] [Abstract][Full Text] [Related]
17. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
Humphreys RE; Hillman GG; von Hofe E; Xu M
Cell Mol Immunol; 2004 Jun; 1(3):180-5. PubMed ID: 16219165
[TBL] [Abstract][Full Text] [Related]
18. Molecular markers (c-erbB-2, p53) in breast cancer.
Agrawal AK; Jeleń M; Rudnicki J; Grzebieniak Z; Zukrowski P; Nienartowicz E
Folia Histochem Cytobiol; 2008; 46(4):449-55. PubMed ID: 19141397
[TBL] [Abstract][Full Text] [Related]
19. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
de Roos MA; van der Vegt B; Peterse JL; Patriarca C; de Vries J; de Bock GH; Wesseling J
Histopathology; 2007 Aug; 51(2):227-38. PubMed ID: 17650217
[TBL] [Abstract][Full Text] [Related]
20. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
Cohen CJ; Hoffmann N; Farago M; Hoogenboom HR; Eisenbach L; Reiter Y
Cancer Res; 2002 Oct; 62(20):5835-44. PubMed ID: 12384546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
